SCHEMBL2368258

SCHEMBL2368258

CCN1CCCC1CNc1ncnc2scc(-c3ccccc3)c12

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
HTT P42858 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
MAPK1 P28482 2/20 0.55
ALDH1A1 P00352 2/20 0.55
NCOA1 Q15788 1/20 0.54
NCOA3 Q9Y6Q9 1/20 0.54
TNF P01375 1/20 0.52
NOD1 Q9Y239 1/20 0.52
ACHE P22303 1/20 0.51
CCNC P24863 1/20 0.51
CDK8 P49336 1/20 0.51
KDM4E B2RXH2 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
POLB P06746 1/20 0.49
KMT2A Q03164 1/20 0.49
ADRB3 P13945 1/20 0.48
FGFR1 P11362 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368375 0.81 LMNA (0.65) LMNAHTTSMN1; SMN2MAPK1ALDH1A1
SCHEMBL2369025 0.80 LMNA (0.61) LMNAHTTSMN1; SMN2MAPK1ALDH1A1
SCHEMBL2368726 0.76 HTT (0.66) LMNAHTTSMN1; SMN2MAPK1ALDH1A1
SCHEMBL3388458 0.76 LMNA (0.64) LMNAHTTSMN1; SMN2MAPK1ALDH1A1
SCHEMBL23598887 0.75 ADRB3 (0.55) LMNAHTTSMN1; SMN2MAPK1ALDH1A1
SCHEMBL31336989 0.74 ADRB3 (0.57) LMNAHTTSMN1; SMN2MAPK1ALDH1A1
SCHEMBL14965102 0.74 POLB (0.54) HTTPOLBKMT2A
SCHEMBL2368203 0.74 ALDH1A1 (0.69) LMNAHTTSMN1; SMN2MAPK1ALDH1A1
SCHEMBL2369277 0.72 CCNC (0.78) LMNAHTTSMN1; SMN2MAPK1ALDH1A1
SCHEMBL2368170 0.72 FGFR1 (0.55) LMNAHTTSMN1; SMN2MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 LMNA 1126/4885HTT 543/4885SMN1; SMN2 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.